Jean-Claude Karp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jean-Claude Karp has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Hervé Curé
Institut Jean Godinot, 1 rue du général Koenig, CS 80014, 51056 Reims, France
2 shared publicationsAntoine Demonceaux
Cabinet Médical, 21, Place du Chapitre, 51100 Reims, France
1 shared publicationCarole Sanchez
Cabinet Médical, 7 bis rue du Chêne, 10430 Rosières Près Troyes, France
1 shared publicationCloé Brami
CHU de Reims, Unité de médecine ambulatoire, cancérologie et hématologie (UMA-CH), avenue du Général-Koenig, 51092 Reims, France, Institut Jean-Godinot, Centre de lutte contre le cancer de Champagne-Ardenne, 1, rue du Général-Kœnig, 51100 Reims, France, Université de Reims, Champagne-Ardenne, 51, rue Cognac-Jay, 51095 Reims, France
1 shared publication- Olivier Bouché
Digestive Oncology Department, CHU Reims, Reims, France
1 shared publication - Philippe Guilbert
Institut Jean Godinot, 51100 Reims, France
1 shared publication
Latest Publications
- 1 November 2016
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 105 (4) , 299-308
Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study
To determine the possible effect of two homeopathic medicines, Ruta graveolens 5CH and Rhus toxicodendron 9CH, in the prevention of aromatase inhibitor (AI) associated joint pain and/or stiffness in women with early, hormone-receptor positive, breast cancer. This prospective, unrandomized observational study was carried out between April and October 2014. Women were recruited in two groups, according to which of the two study centres they attended: one receiving homeopathy in addition to standard treatment (group H) and a control group, receiving standard treatment (group C). All women were treated with an AI. In addition, women in group H also took Ruta graveolens 5CH and Rhus toxicodendron 9CH (5 granules, twice a day) up to 7 days before starting AI treatment. The homeopathic medicines were continued for 3 months. Demographic and clinical data were recorded using a self-assessment questionnaire at inclusion (T0) and 3 months (T3). Primary evaluation criteria were the evolution of scores for joint pain and stiffness, the impact of pain on sleep and analgesic consumption in the two groups after 3 months of treatment. Forty patients (mean age 64.9±8.1 years) were recruited, 20 in each group. Two-thirds of the patients had joint pain before starting AI treatment. There was a significant difference in the evolution of mean composite pain score between T0 and T3 in the two groups (-1.3 in group H vs. +3.4 in group C; p=0.0001). The individual components of the pain score (frequency, intensity and number of sites of pain) also decreased significantly in group H. Nine patients in group C (45%) vs. 1 (5%) in group H increased their analgesic consumption between T0 and T3 (p=0.0076). After 3 months of treatment, joint pain had a worse impact on sleep in patients in group C (35% vs. 0% of patients; p=0.0083). The differences observed in the evolution of morning and daytime stiffness between the two groups were smaller (p=0.053 and p=0.33, respectively), with the exception of time necessary for the disappearance of morning stiffness which was greater in group C (37.7±23.0 vs. 17.9±20.1 min; p=0.0173). These preliminary results suggest that treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may decrease joint pain/stiffness in breast cancer patients treated with AIs. A larger-scale randomized study is required to confirm these results.
- 1 November 2016
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 105 (4) , 299-308
Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study
To determine the possible effect of two homeopathic medicines, Ruta graveolens 5CH and Rhus toxicodendron 9CH, in the prevention of aromatase inhibitor (AI) associated joint pain and/or stiffness in women with early, hormone-receptor positive, breast cancer. This prospective, unrandomized observational study was carried out between April and October 2014. Women were recruited in two groups, according to which of the two study centres they attended: one receiving homeopathy in addition to standard treatment (group H) and a control group, receiving standard treatment (group C). All women were treated with an AI. In addition, women in group H also took Ruta graveolens 5CH and Rhus toxicodendron 9CH (5 granules, twice a day) up to 7 days before starting AI treatment. The homeopathic medicines were continued for 3 months. Demographic and clinical data were recorded using a self-assessment questionnaire at inclusion (T0) and 3 months (T3). Primary evaluation criteria were the evolution of scores for joint pain and stiffness, the impact of pain on sleep and analgesic consumption in the two groups after 3 months of treatment. Forty patients (mean age 64.9±8.1 years) were recruited, 20 in each group. Two-thirds of the patients had joint pain before starting AI treatment. There was a significant difference in the evolution of mean composite pain score between T0 and T3 in the two groups (-1.3 in group H vs. +3.4 in group C; p=0.0001). The individual components of the pain score (frequency, intensity and number of sites of pain) also decreased significantly in group H. Nine patients in group C (45%) vs. 1 (5%) in group H increased their analgesic consumption between T0 and T3 (p=0.0076). After 3 months of treatment, joint pain had a worse impact on sleep in patients in group C (35% vs. 0% of patients; p=0.0083). The differences observed in the evolution of morning and daytime stiffness between the two groups were smaller (p=0.053 and p=0.33, respectively), with the exception of time necessary for the disappearance of morning stiffness which was greater in group C (37.7±23.0 vs. 17.9±20.1 min; p=0.0173). These preliminary results suggest that treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may decrease joint pain/stiffness in breast cancer patients treated with AIs. A larger-scale randomized study is required to confirm these results.
- 1 June 2014
- Published by Elsevier in Bulletin du Cancer
- Vol. 101 (6) , 531-532
La cancérologie intégrative ou l’utilisation des thérapies complémentaires. À propos d’un modèle américain
- 1 June 2014
- Published by Elsevier in Bulletin du Cancer
- Vol. 101 (6) , 531-532
La cancérologie intégrative ou l’utilisation des thérapies complémentaires. À propos d’un modèle américain
- 1 June 2013
- Published by Elsevier in La Revue d'Homéopathie
- Vol. 4 (2) , 51-55
La fatigue en cancérologie : un problème majeur
- 1 June 2013
- Published by Elsevier in La Revue d'Homéopathie
- Vol. 4 (2) , 51-55
La fatigue en cancérologie : un problème majeur